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1. Introduction  
 
The aim of this work consists of pricing a real biotechnology firm 
that is based on a portfolio of several drug development projects at 
different phases. Duffie and Singleton (1999) formulate a system of n 
correlated jump mean-reverting intensity equations to capture a portfolio 
of n entities’ default times. The drawback of their approach is that there 
are a lot of parameters and we have no enough information so as to 
estimate all. This is the reason why the copula approach has been very 
well accepted in recent years as an alternative tool for these situations 
since we can model the extreme situations (or default in this case) under 
a dependence framework by selecting those copula functions with a very 
few number of parameters. Summing up, this is the reason why we use 
them in this study. We simulate situations of common rare events under 
this approach.   
 
The abandonment flexibility - which is the only one that we 
consider in this study and it is quite different from the idea to abandon 
due to a common (specific) catastrophic event which can be extended to 
the remaining projects (one project) – affects each project independently. 
This option is exercised under those situations of expected costs to 
completion higher than the expected cash flow, that is, during the 
investment period for research and development. Including this flexibility 
in a patent is the same as valuing a project with an implicit American put 
option. 
 
2. A portfolio of Research and Development projects 
 
 The assets for the company that will be value consist in a 
portfolio of research and development drugs projects which are patent 
protected. The flexibility inherent in these projects is captured by real 
option methodology. The patent life for these projects is in average 
twenty years. Once the R&D process is completed, the new drug is 
marketed and the company enjoys of a monopolistic situation until the 
expiration of the patent life. From the time being, the drug has to share 
the market with generics, and a sales decreasing is produced until reach 
profits zero1.Another possibility would be that the firm runs out all the 
patent life for R&D without completion. 
 
                                                 
1 The possibility of two different drugs development process would lead a duopoly 
situation, but the basis would be the same (Schwartz 2004). 
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 We can identify three types of uncertainties: the first one is about 
the investment cost required for the completion of the R&D stage of the 
project. The reason is a learning process that occurs while there is 
investment. We capture this one with a cost dynamic described in 
Pindyck (1993) and Schwartz (2004). The second uncertainty concerns 
about the possible free cash flows (FCF) that the drug will obtain once 
that have been marketed. For capturing this one, we will proposal three 
types of processes as Piñeiro and León (2004) recommended. The third 
uncertainty is described by catastrophic events that could lead the failure 
of the project. This one will be described by a Poisson process. 
 
 In all stages the possibility of abandon can be exercise if the 
completion expected cost is higher than the expected cash flow, that is, in 
the research and development period. We also introduce a new dimension 
to our valuation: dependence between projects, that is, in the hypothetical 
case of  a catastrophic event that affected to one project, it could lead a 
contagious effect in the others, which would give a higher probability of 
going bust than the initial predicted for our portfolio. The dependence 
will be introduced in the instantaneous intensity of default for each 
project. This dependence will be simulated with two tools: on one hand, 
we will introduce a process that capture common and specific projects 
effects and sum up in an affine process. On the other hand, we will use a 
well-known tool in credit risk: copula functions. 
 
3. Continuous time model 
 
 The research process for one drug is long and it has an associated 
costs that can vary depend on the development phase will take place. If 
the drug overcomes every phase, it will ready for commercial lunch. In 
our model we implemented a different expected cost to completion in 
each phase for our empirical evaluation. We let the possibility of generic 
entrance once the patent expires and also we use different models to 
capture the dependence among projects to avoid overvaluation or 
undervaluation of our portfolio. 
 
3.1 Cost Dynamic 
 
We follow, in spirit, the modeling of cost uncertainty in 
irreversible investment projects described in Schwartz (2003) and León y 
Piñeiro (2004). The dynamics of the conditional expected remaining 
costs to completion are given by: 
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Where Ks(t) is the expected real cost to complete the ongoing 
phase before starting the next phase. The interpretation for equation (1) is 
straightforward. As the firm continues investing in the R&D, the 
expected remaining cost to completion decreases. However, the firm also 
learns more about its ability to complete the project on time and on 
budget. Prior to the beginning of Phase i, the firm expects that the total 
cost to complete the Phase i research to be Ki(0). Negative shocks to the 
R&D delay the Phase i completion and increase the total development 
cost for the phase, while positive shocks shorten development time and 
reduces the development cost. The drift component in equation (1), 
which is the rate of investment Ij, is a control variable: the larger is the 
investment rate, the lower is the expected cost to completion. This means 
that the investment implies a “learning process” and the expected cost 
decreases only when there is investment. The uncertainty  is called 
by Pindyck (1993) “technical uncertainty” and only can be solved by 
investing. Due to the variance is linear in investment; there will be only 
two possible solution values for the control: invest zero or the maximum 
possible rate. 
( )sdw t
 
 Remark that the stochastic process for the cost dynamic is a 
reasonable representation of uncertainty about expected cost in R&D 
investment for drugs as suggest DiMasi et al (2003) and Schwartz 
(2001). 
 
3.2 Free Cash Flow Dynamic 
 
 We implemented a life cycle model that consists in three parts: 
from the R&D completion date until the sales peak2; from the sales peak 
to the expiration date of the patent; and from the expiration date to the 
time that the firm obtains zero profits. 
 
3.2.1 Stage 1 
 
 For the first stage, we use a Brownian motion model given by: 
 
                                                         (2) *1 1 1( ) ( ) ( ) ( )cdC t C t dt C t dz tα φ= +
 
 
2 According to some papers, it is achieved in the ninth year. 
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Where alpha is the risk-adjusted drift: 
 
               *α α η= −                                                            (3) 
 
And η  is the risk premium. φ  is the volatility parameter and 
 is the increment of a wiener process under the risk neutral 
measure. 
*( )cdz t
 
3.2.2 Stage 2 
 
 For the second stage we propose three alternative life cycle 
models, that is, a Brownian motion, an Orstein-Uhlenbeck and a random 
walk. The key for introducing them is to avoid a possible overvaluation 
of the project (Bollen 1999, León y Piñeiro 2004). 
 
 
3.2.3 Stage 3 
 
 And for the third stage, we assume that the behavior of the FCF 
will be decreasing till getting to zero when the profits are zero, because 
since the patent has expired, the monopolistic advantage decreasing for 
the leader firm due to the entrance of generics until reach zero profits: 
 
                                     *2 1( ) ( ) ,dC t C T dt T t Tδ= − ≤ ≤                            (4) 
Where T is the patent expiration date, C1(T) is the FCF starting 
value for stage two and T* is the time in that the profits are zero and ( )tδ  
is the delta function with values decreasing from T to T* (it captures the 
decreasing effect in profits): 
 
                                        (5) 
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 We also let correlation between  and  given by: ( )idw t
* ( )cdz t
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4. Introducing dependence between projects 
 
 We consider two approaches for introducing the dependence 
among projects. On one hand, we consider a process for specific factors 
and another for common factors. On the other hand, we will use copula 
functions. Both of them try to solve the stylized facts to describe the 
dependence with extreme values: asymmetric as indicated nonzero 
skewness and fat tails as indicated by excess of kurtosis. 
 
 The dependence is introduced by the intensity of default3. Then, 
the survival probability will be given by a Poisson process as Schwartz 
(1999) and León & Piñeiro (2004) suggest: 
 
    0( )
t
idt
prob Tc Ts e
λ−∫> =                                 (7) 
 
 We consider two ways for introducing the dependence. The first 
one is specifying a copula function consistent with the studied empirical 
dependence structure. The problem of this approach is the absence of 
empirical data for intensities of default in R&D companies. The second 
one is specified given marginals ex-ante and inducing then the related 
copula functions. We use the second one for two main reasons: first, as 
we have said before, we do not have empirical data of the intensities of 
default for fitting any copula, and second, this approach lets us to 
compare the grade of undervaluation or overvaluation with the different 
copulas that have been chosen in our pool. 
 
4.1. Fan Yu Approach 
 
 We have introduced a model to give us a first approach of the 
dependence between projects and let us to compare these results with a 
later copula approach. We use Fan Yu approach (2003), which consists in 
modeling the dependence through the individual intensity of default with 
common and specific factor processes given by: 
 
              ( ) ( ) ( )i t F t Gi tλ α β= + +                                   (8) 
 
Where beta is the factor loading for the common factor process 
F(t), alpha is a free-adjust parameter and G(t) is the specific factor. And 
                                                 
3 We assume that ( )i tλ  exhibit continuous margins for modeling it with the pool of 
copulas of our study. 
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because the individual intensities are linear functions of the processes 
considered, then they are affine processes and we can apply known 
mathematical tools. The parameter beta controls the proportion of the 
total variation in the default intensity that is attributed to the common 
factor. With beta zero the default correlation will be zero. The common 
and specific factors will follow CIR’s processes that ensure a positive 
value for the variable under study. The expressions are given by: 
 
      1 1 1( ) ( ( )) ( ) ( )dF t k F t dt F t dw tθ σ= − +                     (9) 
 
         2 2 2( ) ( ( )) ( ) ( )i i idG t k G t dt G t dz tθ σ= − + i
                                                
               (10) 
 
 
Where  and  are independent Wiener processes. ( )dw t ( )idz t
 
The initial value for the factors will be set to their respective long-
run means. The factor loading beta will be treated as a free parameter. 
The constant coefficient alpha is chosen such that the cumulative default 
probability at the ten year horizon is equal to 1%, according with some 
estimation in Duffie (1999) and Driessen (2005). Since the model will be 
numerically implemented because it has not a closed-form solution, a 
discrete explicit solution of CIR process will be necessary as we will see 
in section five.  
 
4.2. Copula Approach 
 
  For the copula approach, we use a pool of both extreme value 
Archimedean copulas and elliptical copulas. The pool consists in 
Gumbel, Clayton, t and Gaussian copula. We will compare different 
scenarios with different parameters and copulas to capture the grade of 
overvalue or undervalue compare with a non-contagious effect scenario. 
We generate random samples of these and we introduce in our model in 
order to capture the dependence through the intensity of default4. Notice 
that the idea is not fitting a data with a specified copula because we have 
not time series data of the company, but capture the dependence through 
 
4 The key is to insert the intensity of default in the survival probability given by 
0( )
t
idt
prob Tc Ts e
λ−∫> =  
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different copula functions among projects5. The way for introducing the 
dependence will be generate samples for a chosen copula and these 
samples will be taken as intensities of default for one project.  Note that 
the dependence is capture through the copula function that generates the 
samples and that dependence affect to all intensities of default. 
 
4.2.1 Brief introduction to copulas 
 
Copula functions are adapted tools to construct multivariate 
distributions. The copula extends the concordance notion to the 
continuous framework. We take the marginal distributions, each of which 
describes the way in which a random variable moves “on its own,” and 
the copula function tells us how they “come together” to determine the 
multivariate distribution of the portfolio of variables considered; that is, 
 
Definition 1 A copula is a function that joins a multivariate probability 
distribution to a collection of univariate marginal probability functions.  
 
Properties According to Nelsen (1998) a N-dimensional copula is a 
function C with the following properties: 
 
1. Dom C is [0,1]N, 
2. C is grounded and N-increasing6, 
3. C has margins Cn which satisfy Cn (u)=(1,1,…,u,…,1,1)=u   for all u in 
the domain. 
 
Copulas are invariant through strictly increasing transformations 
of the random variables considered. The copula also takes into account 
phenomena due to depended extreme events. Really, this is the most 
important point of interest for us: copula provides more information due 
to rare events that occurs with lower probability in the distribution tails 
but occurs. So, copula lets us to capture them. Sklar theorem let us to 
study the dependency structure of multivariate distributions without 
studying marginal distributions; that is, 
 
Theorem 1 If F is a N-dimensional distribution with continuous 
marginals F1…FN  then F has a unique copula representation (Sklar, 
1959): 
                                                 
5 Of course is straightforward to introduce time series data one time the scenarios have 
been implemented (a likelihood method –it has been implemented by us- would be the 
most recommended option to this proposal). 
6 C is N-increasing if the C-volume of all N-boxes whose vertices lies in IN are positive. 
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   1 1 1( ,..., ,..., ) ( ( ),..., ( ),..., ( ))n N n n N NF x x x C F x F x F x=                (11) 
 
Also Deheuvels (1981) showed that each multivariate distribution 
has at least one associate copula function, and this copula is unique when 
margins are continuous. However, as Frees and Valdez (1997) notes, is 
not always obvious to identify the copula. More exactly, Durrleman, 
Nickeghbali and Roncalli (2000) noted that a misspecification of 
marginals leads to a biased estimation of the copula function, and the 
solution would be consider the copula function without any marginal law.  
 
 Within of the large family of copulas, we will be interested in two 
groups: Elliptical copulas and Archimedean copulas. The first one 
includes Gaussian copulas and t copulas. The second one includes 
Gumbel, Clayton and Frank copulas. 
 
 Gaussian copulas provide a very simple framework for studying 
the dependence effect7. This one does not permit tail dependence, but it 
could help to match the effects of introducing the dependence. A 
drawback, also shared by t copulas, is the big number of parameter 
necessary: a correlation matrix of ( 1).
2
nn −  elements. If the Gaussian 
copula fits the data well, the correlation matrix suffices to describe the 
dependence. 
 
 T copulas need to specify the degrees of freedom and the 
correlation matrix8 too. However, this one captures extreme value effects 
because it is asymptotically dependent in both the upper and the lower 
tail. For fixed correlation structure, the strength of the tail dependence 
increases as the degrees of freedom decreases; and for fixed degrees of 
freedom, the tail dependence increases as the correlation structure 
increases. So, the parameters needed are ( 1). 1
2
nn − + . 
 
                                                 
7 Lower tail dependence with parameter Lλ   means that as , the probability 
mass that is in the lower square [0,u]x[0,u] tends to zero like 
0u →
Lλ .u and not like , the 
area of the square. This means that there must be a rather strong singularity of the 
copula’s density in the lower left corner (0,0). Analogous judgment for higher tail 
dependence is followed.   
2u
8 Note if we increase the degrees of freedom, t copula converges to Gaussian copula, 
more exactly, with 30υ →  the different are negligible. 
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 On the other hand, the advantage of Archimedean copulas is 
given by the lower number of parameters needed for modeling them. 
More exactly, we only need to specify the generator function for the 
copula chosen. Also we have generators with a lower number of 
parameters (in our case with one or two parameters). Archimedean 
copulas are also exchangeable; the dependency between any two or more 
different variables does not depend on the question which pair is chosen. 
This is a good notice for assessing portfolio with homogeneous projects 
as in our case (all drugs projects in R&D phases). Gumbel copulas are 
interested because they have higher tail dependence. The idea is that a 
higher intensity of default for one project due to catastrophic events will 
be followed by a higher intensity of default by others projects. So, this 
one is, a priori, the best election for our proposal. Clayton copulas have 
lower tail dependence, and frank copulas are symmetric. 
 
 Details about sampled generations will be given in section five. 
 
5. Model Implementation 
 
 Due to the interest in giving the details about copula sampling and 
the algorithms used by us, we divided this section in three parts. In the 
first one we give the discrete expression that has been implemented; in 
the second one, we give a more exhaustive analysis of sampling methods 
and in the third one, we explain the stopping rule algorithm. 
 
5.1 Discrete versions of cost and FCF dynamics 
 
 Because we cannot obtain the portfolio value with a closed-form 
solution we need to consider the discrete version of given equations, and 
employ for solving a numerical solution algorithm as we have said 
before. The discrete version of cost dynamic equation (1) is given by: 
 
       ( ) ( ) ( ) ( )s s s s sK t K t I K t tsσ ε+ Δ = − Δ + Δ                      (12) 
 
 The discrete version of equations (2) and (4) are respectively: 
 
  * 21 1( ) ( )exp[( 0.5 ) ( )]cC t C t tα φ φ ε+ Δ = − Δ + Δ                     (13) 
 
                               (14) 2 2 1( ) ( ) ( ) ( )
t
t
C t C t C T u duδ
+Δ
+ Δ = − ∫
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Where ( )c tε  is a correlated standard normal variable with 
parameter ciρ  between  and . The correlation between two 
different phases is assumed equal to zero (León y Piñeiro 2004). T is 
defined as the remaining life in years of the patent from nowadays till 
expiration or stage one. And for equations (9) and (10) we use the 
transition density function of them which is known
( )idw t
*( )cdz t
9 for getting a discrete 
solution of the CIR processes: 
 
 
1
'1
1
(1 )( ) [ ( )]
4
k
d
eF t v
k
σ χ
− Δ−=                                 (15) 
1
1
1
2
1
4( ) ( )
(1 )
k
k
k ev t F t
eσ
− Δ
− Δ= − Δ−                                (16) 
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'2
2
(1 )( ) [ ( )]
4
k
i
eG t v
k
σ χ
− Δ−= d                                (17) 
 
    
2
2
2
2
2
4( ) ( )
(1 )
k
ik
k ev t G t
eσ
− Δ
− Δ= − −Δ                                (18) 
 
    T
N
Δ =                                               (19) 
 
Where  is the non-centered Chi function that can be 
expressed as a centered Chi function and 
' ( )d vχ
Δ  is the time step size. k1 and 
k2 are parameters of the CIR processes, and also the volatilities. 
 
5.2 Methods for simulating draws from a chosen copula 
 
 Assume a bivariate copula in which all of its parameters are 
known (fixed or estimated them). The task is to generate pairs (u,v) of 
observations of [0,1] uniformly distributed random variable. (u,v) whose 
joint distribution function is C. To reach this goal, we can use two 
methods: the conditional distribution technique, and the Marshall and 
Olkin’s algorithm for the compound construction of copulas. 
 
 
 
                                                 
9 For a detailed study see Glasserman 2003. 
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5.2.1 The conditional distribution technique 
 
 The algorithm for the conditional distribution technique 
(Cherubini, 2001) is: 
 
-Compute two independent r.v.s. ( , ) [0,1]u v ∈ , 
-U is the first draw we are looking for.  
-Compute the cuasi-inverse function of  . 1( ) ( )u uC v v C w
−⇒ =
 
 For multivariate generation, we only need to consider that the 
draw Fn is extracted of the conditional distribution 1 1( ,..., )n nCn F F F − . 
 
 The drawback of the conditional distribution technique is that it 
fails very quickly if the number of dimensions becomes just moderately 
large (bigger than 4), because either the analytical expressions become 
impossible to handle or because deriving the conditional distribution on 
the k-th level involves taking k cross-derivatives of the distribution 
function. Each numerical evaluation of a derivative of a function involves 
the subtraction of two numbers very close to each other, and scaling up 
the different. At each of these subtractions several significant digits in 
accuracy are lost. So, other methods more robust and easy to compute are 
needed. 
 
5.2.2 Marshall and Olkin’s method  
 
 The key point in the M&O method is that conditional on the 
realization of γ , the random variables Ui are independent. This 
conditional independence property was exploited in the proof of the 
algorithm10. It has a similar function to the conditional independence 
which allowed Schömbucher to derive the large portfolio loss distribution 
in the one factor Vasicek model11. 
 
 The algorithm is12: 
 
-Generate a latent r.v. γ  having Laplace transform τ . 
                                                 
10   See Marshall and Olkin (1988) for details: Algorithm for the compound construction 
of copulas. 
11 See Credit Derivatives pricing models, Schömbucher (Wiley and Sons). 
12 See Frees and Valdes (1998) for details of the Marshall and Olkin’s algorithm 
implementation. 
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-Independently of the previous step, generate U1,…,Un independent 
random variables. 
-For k=1…n, calculate 1 (k k k
*)X F U−= = , where 1( lnk kU Uτ γ= − )
n
.  
-F is given by 1 11 1 1( ,..., ) ( ( )) ... ( ( ))n nF x x F x F xτ τ τ− −⎡ ⎤= + +⎣ ⎦ . 
-Each Xk is the draw looked for. 
  
 Draws from the M&O algorithm are straightforward calculated 
for most copulas of interest that are generated by compounding methods. 
It can be easily implemented for high dimension. Needless to say, this 
additional latent variable is not always easy to simulate and to calculate 
the Laplace transform. 
 
5.3 Algorithm for the stopping rule 
 
Our election will be based on the optimal stopping algorithm of 
Longstaff and Schwartz (2001) that combine Monte Carlo simulation 
with least squares regression that was implemented in León and Piñeiro 
(2004).  The algorithm searches for the optimal stopping along 
each path by backwards induction. It is assumed that the option to 
abandon the project can be only exercised once and before the approval 
for the market launch of the drug. Note the optimal stopping time rule 
consist of obtaining for each path the minimum value that the abandon is 
better than continuing. 
 More exactly, once we have simulated random samples from 
copulas, or we have introduce the values obtained by Fan Yu approach in 
the Poisson process that describe the probability of success at each phase, 
we simulate our model getting different paths in the simulation, and we 
advance by each one until to reach the expiration date or to execute the 
abandon option. Then we discount the FCF until the time in that we are 
valuing the firm, and doing the mean of all paths implied in the process 
we get the value that we are looking for. 
 
  We obtain a payoff matrix with elements ( , )V i jΔ . The procedure 
to get ( , )V i jΔ is: (a) start at time zero, (b) move forward along each path 
till the first stopping occurs and we will denote ji* as the optimal stopping 
date for path i,  (c) then discount all the cash flows to time zero and (d) 
take the average of  the Np paths. In the end, we estimate the value of the 
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portfolio by discounting the FCF to time zero and averaging them over 
all paths according to the next expression13: 
 
        
1
0
1 1
1 exp[ ( )] ( , )
pN N
j j
i jp
V r
N
λ
= =
= − + Δ∑∑ V i jΔ
                                                
                          (20) 
 
Note that the intensity of default is introduced in the valuation as 
an increment in the discounted rate. We also need to consider the 
(possible) cash of the firm that must be added to the total value of the 
firm that is obtained in our algorithm. 
 
6. Data and parameters 
  
  We use data of different sources to adjust our models. In concrete, 
we use the data of León and Piñeiro (2004) for the PharmaMar valuation, 
and also data from financial analysts’ reports corresponded to this year. 
All monetary values are expressed in euros. 
 
6.1 Portfolio composition 
 
 The process of drug development is lengthy, complex and risky. 
Before a new drug can reach the market, it must pass through the 
following sequential stages: discovery; preclinical testing; phases I, II 
and III from clinical trials; submission to either the European Medical 
Evaluation Agency or Food and Drug Administration (FDA) and finally, 
phase IV trial. 
 
The most advance drug is Yondelis that is waiting for the 
approval of EMEA (European Medical Evaluation Agency). Aplidine is 
the second more advanced that has shown to be active in a larger number 
of cancer types. Kahalahide-F has as main indication prostate cancer and 
ES-285 has shown evidence of solid tumors. Meanwhile for the 
preclinical one, since it is in a very early stage of R&D joint with the lack 
of information from PharmaMar, it is unknown what sort of pathology 
this compound could be effective. 
 
Our portfolio consists in five drugs: Yondelis, Aplidine, 
Kahalahide-F, ES-285 and Preclinical 5.  To be precise, at simulation 
moment there are two drugs in phase I (Kahalahide-F and ES-285) and 
 
13 See León and Piñeiro (2004) for a detailed explanation of the algorithm. 
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two in phase II (Aplidine and Yondelis). Also a exist four compounds 
more in preclinical testing, but we consider only the compound in the 
most early phase as bound of all of them (Preclinical 5). The reason is 
simple: on one hand, Preclinical 5 has the bigger time expected to 
completion and the lower initial FCF, on the other hand, the bigger 
expected cost of all preclinical drugs (it works as lower bound for costs). 
Also it permits us to simplify the dimension of our problem for copula 
constructing. 
  
6.2 Copulas parameters 
 
 Copula functions have been implemented with marginal 
distributions as exponential functions, with parameter T. More 
concretely, the parameter is fixed to the expected remained time to 
completion for each drug. So we have:  16.75, 17.75, 18.50, 19.25 and 
22.25 years for each component respectively. The explanation for our 
marginal distribution function election is to ensure the positive value of 
our latent variable (intensity of default) and due to the exponential 
distribution function shape, to get the greater part of values in the lower 
part of the shape, and only higher values in the tail with a lower 
probability. This idea capture the catastrophic event process: if not usual 
to occur, but if it occurs, values can be very high. Of course, it is a priori 
specification, and a more detailed study with empirical data could help to 
choose another one (Gaussian or gamma distributions could be an correct 
election). But due to the characteristic of our study, that is, to introduce 
dependence between projects as a early approximation, such marginal 
functions are considered by us a good idea. 
 
 Also for Archimedean ones, the dimension specified has been 5 
and the parameters chosen have been 2 or a vector with two parameters 
(2,4). For the Gaussian copula also we introduce correlation between 
each project with parameter 0.5, and for the t copula the same correlation 
and 9 as the degrees of freedom. Again the copula parameters and 
correlation choice are arbitrary: we weigh up both types of copulas with 
correlation factor 0.5 to introduce the homogeneity of the entry of a 
possible catastrophic event for all projects independently of the drug14. 
Finally, we have generated a matrix for each type of copula with 60000 
                                                 
14 Of course an exercise of calibration would be the most appropriate tool for getting 
fitted values according to the empirical dependence structure. However, we do not have 
empirical data for default intensities so a trial and error method has been followed by us 
to obtain these values. 
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paths and five columns (one for each drug’s intensity of default). So we 
have matrixes of size 60000 x 5.  
 
6.3 Phases parameters 
 
 The expected average lifetime, in years, for each phase is fixed 
according to Sweeny (2002) and Tang (2002): 3.5 (preclinical), 1.5 
(phase I), 2 (phase II), 2.5 (phase III) and 1.5 (approval). 
 
6.5 Costs parameters 
 
 According to analyst’ reports, we will assume as total costs to 
PharmaMar exactly 2/3 of the standard pharmaceutical costs. This 
reduction is due to the short toxic level since these compounds are 
obtained from marine organism. The expected cost to a certain phase is 
the same for each therapeutical line for any compound. For preclinical 
compound, the forecast of the cost is the same for phases I, II, III and 
approval due to the lack of data. The expected cost for a given phase will 
be the same for any therapeutical line and this value will be independent 
of the compound that the therapeutical line belongs to. The reason is the 
number of pathologies treated with each compound is the same in each 
phase. For obtaining the annual rate of investment per phase Is, we divide 
the expected cost to complete phase s, ks, by the expected lifetime of 
phases s given in subsection 6.3. The volatility parameter sσ  can be 
obtained from: 
                             
2
2
2var [ ( )] 2
s
t s s
s
k t kσσ= −
?                                              (21) 
 
We need also estimations for both the square root of   
and k
var [ ( )]t sk t?
s, which can be found in DiMasi et al (2003). The resultants 
estimates of sσ are 0.96, 0.91, 0.97 and 0.81 to phases preclinical, I, II 
and III respectively. In the approval phase, due to all events that affect to 
a drug are of civil service, the volatility is fixed to zero.  
  
6.6 FCF parameters 
 
 FCF are the 33.45% of the sales. We compute the annual peak 
sales considering that the sales in Europe are a 35% of total sales and the 
royalties. We will take as percentage the average of the total sales with 
value 15.12%. The peak sales for the preclinical compounds are obtained 
as the average of the clinical compounds’ peak sales times five (five 
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compounds). For computing the peak sales for Yondelis, we consider the 
amount of 538.27 million for PharmaMar business in Europe. The annual 
peak FCF is 331.25 million which comes from adding up both 180.05 
and 151.20, where 18.05(151.20) is equal to 538.27x0.3345 
(999.64x01512). So the quarterly FCF is 82.81 million. For all other 
compounds the procedure is similar. 
 
We use two drifts in our model to compare the sensitivity of the 
model to changes in the drift. The first one -0,291- was used in León and 
Piñeiro (2004) and it was obtained from Yondelis and it was the same for 
all drugs dynamics since we have not enough information for the rest. 
The second one -0.115- is proposed by DiMasi and it is calculated from 
different studies of R&D pharmaceutical companies. This second one 
assumes lower expectations about future FCF, so the expected results 
must be lower than with the first one because FCF is lower now. We set a 
small correlation between the stochastic process for cost and cash flows 
(-0.10) according to León y Piñeiro (2004). This value will be increasing 
in absolute value as we move to more advanced phases in R&D. The idea 
is based on that more successful projects take a shorter time to develop, 
so their cost are lower and their cash flows are higher. The annual 
volatility parameter φ  is fixed to 0.38 which is the sample standard 
deviation based on daily returns of Zeltia (2003, January to April period). 
In the end, when the patent expires the sales decreasing because of 
generics. The drop set for the first 6 years is fixed according to analysts: 
30%, 20%, 15%, 15%, 10% and 10% respectively. 
 
6.7 Other parameters 
 
 The interest rate –denoted as r- will be assumed constant for 
simplicity, and it has been fixed to 1.68%15. The risk premium 
considered is 6% than correspond to a *α of  0.232. 
 
 PharmaMar has in cash an amount of 120 millions of euros that 
we will have to add to the total value of the compounds for the valuation. 
 
 In each compound we use 60000 simulations with quarterly steps, 
that is, = ¼. Δ
 
                                                 
15 Since the internal rate of return –i-  for the ten-year German bond is 3.73% at May 30, 
2003, and given the inflation target denoted by eπ  by the ECB of 2%: (1 )ln (1 )e
ir π
+= + . 
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7. Simulation results 
 
 Our task is to evaluate the portfolio value introducing dependence 
and compare the results without dependence. Table 3 shows the value 
obtained by León and Piñeiro (2004). Table 4 shows our results. We have 
divided it in two: table 4.a shows the results with drift value of 0.291, and 
table 4.b with 0.115. Note that there is three columns: value with 
flexibility (abandon option and dependence is included), without 
flexibility (only dependence is included) and option value. In all of them 
stochastic character is given to the variables. The value of the whole 
portfolio is given by adding all individual values and the cash of 
PharmaMar. Again the higher value  correspond to Yondelis equal that in 
León and Piñeiro (2004) due to the lower uncertainty, and the value 
decrease when increase the cost and FCF volatility, that is, in preclinical 
compound.  
 
Results obtained with drift 0.291 and Archimedean copulas –
tables from 4.1 to 4.6- have higher value than obtained in León and 
Piñeiro (2004). Two possible answers: on one hand, the intensity of 
default is introduced via copulas have a lower effect on the drugs’ values, 
on the  other hand, calibration no play any role in the simulations and the 
bias could be evident.  However, we are worried on how to obtain higher 
option values and in this case are three times in average bigger. Effects 
introduced by two parameters do not change the results so much. The 
random walk introduced in both papers for the drugs’ behavior avoids a 
possible overvaluation and reject a negligible value for the abandon 
option. An Orstein-Uhlenbeck (OU) process produces very similar results 
to the random walk as we have checked in the simulations. Values 
obtained with elliptical ones are negative. Why is it? The reason is 
simple: t and Gaussian copulas give very higher values for intensities of 
defaults due to the input values for sampling them. Remember that these 
values are not calibrated and the correlation matrix is introduced at 
random as an exercise of introducing dependence among projects. Also, a 
marginal misspecification and or their parameters could lead a very 
different result (Durrleman, Nickeghbali and Roncalli, 2000). 
 
Another approach used for introducing dependence is with Fan 
Yu model (table 4.9). In this case, control variable –a vector in our case- 
is introduced weighting up heavier the preclinical compounds than the 
other one. The idea underplayed is that preclinical stages are more 
sensible to contagious effects. Values obtained with this proceed are one 
magnitude order lower than copulas approach but positive. The reason 
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could be the CIR process followed by the intensity of default which 
values are very different of the copulas approach16.  Of course, again 
calibration plays no role in our results and it could lead an important bias 
in the results. So, we conclude that the default correlation in reduced-
form models can be quite sensitive to the common factor structure 
imposed on individual default intensities. It leads to consider as an option 
easier to calibrate copulas due to the lower number of parameters to 
chose. 
 
 Changes in the drift introduce a big effect in the compounds’ 
prices. Tables 4.10 to 4.18 show the results. Again Yondelis has the 
higher value, and it decrease as we increase the time to maturity of the 
drugs due to higher uncertainty in costs and FCF. The results obtained 
are lower than original drift values. However, option values increases a 
lot. Concretely, we observe that a significant increase in the option value 
punishes much the drugs’ values. Another important feature to emphasize 
is that, with new drift, the introduction of the abandon option leads a 
positive value that the model without abandon does not capture as we can 
see in table 4.10 and row ES-285 (with a option value of €7.43 millions). 
We avoid a possible undervaluation that would have been taken without 
flexibility (and of course with Net Present Value method)17. Again 
elliptical copulas punished a lot the price for each drug due to the 
reasoning previously exposed (negative values are obtained). Now Fan 
Yu model shows values more accorded to copulas values, and the option 
value is increased as we have more volatility in the drugs (control value 
parameters have not been change from the previous drift). 
 
8. Sensitivity Analysis 
 
 We have performed three analyses: first one is oriented to capture 
the changes in prices versus drifts. In the second one we illustrate the 
idea that an increase in the time horizon is accompanied by a decrease in 
the survival probability. In the third one, we show that an increase in the 
interest rates leads an increase in the option value to abandon. The first 
one has been calculated for Yondelis because drifts for all compounds are 
based on Yondelis (more advanced compound).The second one is for the 
whole portfolio and all copulas are showed. In the last one, Yondelis 
again is studied for the same reason as before. 
                                                 
16 If we set control variable beta to cero, project values are only a little bigger, and the 
option value changes only about 2%. 
17 Exactly we obtain a NPV for ES-285 of -€89.856 millions (clearly the drug is 
undervalued and the project would be avoided with this method). 
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  The idea of a time decreasing survival probability captures the 
increased in the completion phase expected cost. Figure 1 shows the 
whole portfolio survival probability if we increase the time horizon (in 
years). We observe that the portfolio survival probability starting from 
one year decreases a lot of. Concretely, bigger effects are produced by 
elliptical copulas, while Archimedean ones punish less (remember the 
higher values for intensities default obtained with elliptical ones). Then 
decreasing time survival probability drives higher option values for 
shorting time of the patent life and lower option values for bigger ones. 
 
Changes in drift have been explained in section 7. Sensibility to 
these changes is very large: depending on what expectation about future 
growth is chosen –materialized in the drift value-, very different results 
are obtained indepently of the copula studied. This result could explain 
the very different target price for Zeltia fixed by analysts. Figure 2 
showed the exponential character of the drift for Yondelis value. We 
observed that small increments in drift value lead to large increments in 
Yondelis value so also increase a lot the whole portfolio valuation. 
Remember that as we have stressed before, small drift values are 
associated with higher option values for abandoning which is showed in 
figure 3 (also for Yondelis). It is according to the results obtained by 
León and Piñeiro (2004). Figure 4 shows that higher expectations about 
profits are associated with lower total percentage of abandoned paths18. 
 
Figure 5 shows that a higher real interest rate drives to a higher 
option value to abandon according to León and Piñeiro (2004). 
 
9. Extensions 
 
 An extension applicable to the cost dynamics would permit to 
obtain closed-form solutions and a dynamic learning process. We follow, 
in spirit, the modeling of cost uncertainty in irreversible investment 
projects described in Schwartz (2003) and León y Piñeiro (2004). The 
dynamics of the conditional expected remaining costs to completion 
would be given by: 
 
  ( ) ( ),0i i i idK t I dt dw t t iσ τ= − + < <                         (22) 
 
                                                 
18 Because all drifts for all components are based on Yondelis due to lack of data for the 
rest, we perform sensibility analysis only for Yondelis.  
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( ) ( ),0j j jdK t dw t t iσ τ= < <                                    (23) 
 
                              ( ) ( ),0j j j jdK t I dt dw t tσ τ= − + < <                         (24) 
 
The interpretation for equation (22) and (24) is straightforward. 
As the firm continues investing in the R&D, the expected remaining cost 
to completion decreases. However, the firm also learns more about its 
ability to complete the project on time and on budget. Prior to the 
beginning of Phase i, the firm expects that the total cost to complete the 
Phase I research to be Ki(0). Negative shocks to the R&D delay the Phase 
i completion and increase the total development cost for the phase, while 
positive shocks shorten development time and reduces the development 
cost. Equation (23), on the other hand, captures the idea of learning 
process, that is, revisions in the firm’s expectation on the cost for 
completing Phase i research also brings about revisions in the Phase j 
expected cost to completion (i<j).  
 
 The drift component in equation (22) and (23), which is the rate 
of investment Ij, is a control variable: the larger is the investment rate, the 
lower is the expected cost to completion. This means that the investment 
implies a “learning process” and the expected cost decreases only when 
there is investment. The uncertainty  is called by Pindyck (1993) 
“technical uncertainty” and only can be solved by investing. Due to the 
variance is linear in investment in equation (22) and (23), there will be 
only two possible solution values for the control: invest zero or the 
maximum possible rate. Also with equations (22) and (24) we can get a 
closed-form solution for the “first hitting time density” (which is not 
normal) of an arithmetic Brownian motion with drift I
( )idw t
j and variance jσ  : 
 
       
2
1 1
1 1 1/3 3/ 2 2
1 1 1 1
(0) [ (0) ]( ) exp
(2 ) 2
K K τφ τ σ π τ σ τ
1 1I⎧ ⎫− −= ⎨ ⎬⎩ ⎭
                   (25)   
 
And the cumulative density function for the first hitting time is19: 
1 1 1 1 1 1 1 1
1 1 1/ 2 2 1/ 2
1 1 1 1 1
(0) 2 (0) (0)( ) 1 ( ) expK I I K K IN Nτ τφ τ σ τ σ σ τ
⎧ ⎫ ⎧ ⎫+ − − += − + ⎨ ⎬ ⎨ ⎬⎩ ⎭ ⎩ ⎭
                                                
        (26) 
 
 
19 For details see Karatzas and Shreve (1991) and León (2005). 
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 Since the  and  are correlated we can rewrite the 
expected research cost as: 
1( )dw t 2 ( )dw t
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2 1 2 1 1 1 2 2 1
1
( ) (0) ( (0) ) 1 ( )K K K I Zστ ρ τ ρ σσ= − − − − τ          (27) 
 
 Where 2 1( )Z τ  is a normal random variable with mean zero and 
variance 1τ . 
 
 Therefore we can write 2 1( )K τ  conditionally normal with mean 
2
2 1
1
(0) ( (0) )K K 1 1I
σρ τσ− −  and variance 
2 2
2 11 ρ σ τ− . Remark that the 
stochastic process for the cost dynamic is a reasonable representation of 
uncertainty about expected cost in R&D investment for drugs as suggest 
DiMasi et al (2003) and Schwartz (2001). 
 
 Another possible solution for getting more accuracy solutions 
could be to introduce multivariate dynamic models for copulas. It has 
been studied by Schömbucher and Schubert (2001) and would permit us 
to understand the particular specification of copula has on the dynamics 
of survival probabilities in the model. For more details and proofs the 
reader is referred to this paper20. Also specific construction of copulas or 
change in marginal functions may be to lead different solutions of given 
above. Of course, a calibration exercise would be the best adjust for 
choosing the right copula and its parameters. 
 
 Finally, we could model the intensity of default introducing 
different copulas where the marginal distribution of ( )i tλ   is Pareto and it 
follows a gamma distribution21.  
 
10. Conclusions 
 
This paper studies the valuation of a portfolio of R&D projects 
with real options and introducing dependence between them to capture 
catastrophic events. The approach proposed by us could be used for 
valuing companies with assets that consist in a R&D projects –patent or 
                                                 
20 See also Multivariate Continuous Time Models through copulas, by Shang Chan 
Chiou. 
21 It is being developed by Gea and León (2006). 
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not protected- and highly volatiles in FCF or costs. We allow the 
flexibility of abandonment at any time during the R&D process. We also 
permit extreme value situations that lead dependence in the projects 
behavior. We capture these with two models: a reduced-form model and 
copula functions. Copulas permit us to consider a lower number of 
parameters for introduced dependence effects. Also we consider a 
reduced-form model proposed by Fan Yu (2005) by capture extreme 
values effect. A real simulation is run with a real company. Concretely, 
in our study we use a real portfolio coming from PharmaMar company to 
illustrate numerical examples. It is a portfolio of patents for oncological 
drugs. Patent protected projects considered are in preclinical phase or in 
clinical phases. The value of the portfolio is calculated as the sum of the 
R&D projects. We capture uncertainty in the cost to completion of the 
project, uncertainty in the FCF once the drug is launched and dependence 
between projects modeled as extreme situations of defaults with copulas. 
We have modeled the evolution of the FCF according to León and 
Piñeiro (2004) and allowing the possibility of the generic entranced once 
the patent expires. Costs are modeled indepently for each drug according 
to Schwartz (2004) and León and Piñeiro (2004). Catastrophic events are 
captured in our model and contagious effects bring about them too. More 
exactly, dependence is introduced by a reduced-form model proposed in 
Fan Yu (2005) and copulas functions, with a static model permitting 
dependence among projects and different phases. It is shown that 
Archimedean copulas give a more approximated result to the market 
value specifying a lower number of parameters; and the sensibility to 
increase these are very low. Also is showed that the reduced-form model 
considered is quite sensitive to the common factor structure imposed on 
individual default intensities. The higher drift value considered, the lower 
abandon option value is obtained. We also have obtained that the project 
value –and then the whole portfolio- increases exponentially with the 
drift value. So it can explain very different values fixed by analysts’ for 
Zeltia share. Also percentage of abandon paths is decreasing in the drift 
value. Another variable with an important effect in our model is the 
interest rate: higher interest rates lead bigger option values. Finally, we 
showed that an increased in the time to completion for the project to 
cause a decreasing in the probability of survival for the whole portfolio, 
and the intensity of this fallen depends on the copula considered (in our 
case t copula produces the most big effect in the survival probability).  
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Table 1. Expected cost per phase (euro million 2003) 
 Kprec,0 KI,0 KII,0 KIII,0 Kap,0
Yondelis   9.28 40.58 2.07 
Aplidine   18.55 40.58 2.07 
Kahalalide  0.99 7.95 17.39 0.89 
ES-285  1.99 7.95 17.39 0.89 
Preclinical 5 57.84 3.31 13.25 28.99 1.48 
 
Table 2. Data to model FCF (euro million 2003) 
 Peak sales Peak FCF Initial FCF 
Yondelis 1537.90 82.81 1.59 
Aplidine 1534.47 82.63 1.18 
Kahalalide 799.22 43.04 0.49 
ES-285 799.22 43.04 0.39 
Preclinical 5 1214.65 65.41 0.24 
 
Table 3. Valuation of PharmaMar without dependence between projects 
(euro millions, 2003) 
 Value with 
option 
Value without 
option 
Option Value 
Yondelis 436.52 436.36 0.16 
Aplidine 283.01 282.79 0.21 
Kahalalide 106.20 106.06 0.14 
ES-285 81.87 81.69 0.18 
Preclinical 5 18.86 8.70 7.17 
 
 
Table 4.a Valuation of PharmaMar with dependence between 
projects(euro millions, 2003) 
Drift 0.291 
Gumbel param 2 
Value with 
option 
Value without 
option 
Option Value 
Yondelis 547.44 547.11 0.33 
Aplidine 503.36 503.00 0.36 
Kahalalide 236.84 236.66 0.17 
ES-285 212.66 212.44 0.44 
Preclinical 5 158.59 157.66 0.93 
 
 
 
 
 26
Table 4.2.a Valuation of PharmaMar with dependence between 
projects(euro millions, 2003) 
Drift 0.291 
Gumbel param 
2,4 
Value with 
option 
Value without 
option 
Option Value 
Yondelis 546.82 546.49 0.32 
Aplidine 503.13 502.75 0.37 
Kahalalide 237.24 237.07 0.17 
ES-285 212.65 212.35 0.30 
Preclinical 5 155.68 154.98 0.70 
 
Table 4.3.a Valuation of PharmaMar with dependence between 
projects(euro millions, 2003) 
Drift 0.291 
Frank param 2 
Value with 
option 
Value without 
option 
Option Value 
Yondelis 547,16 546,83 0,32 
Aplidine 503,13 502,75 0,37 
Kahalalide 237,24 237,07 0,17 
ES-285 212,65 212,99 0,33 
Preclinical 5 157,84 157,39 0,45 
 
Table 4.4.a Valuation of PharmaMar with dependence between 
projects(euro millions, 2003) 
Drift 0.291 
Frank param 2,4 
Value with 
option 
Value without 
option 
Option Value 
Yondelis 547,81 547,48 0,33 
Aplidine 503,25 503,00 0,25 
Kahalalide 235,57 234,99 0,57 
ES-285 211,00 210,54 0,45 
Preclinical 5 156,73 156,23 0,50 
 
Table 4.5.a Valuation of PharmaMar with dependence between 
projects(euro millions, 2003) 
Drift 0.291 
Clayton param 2 
Value with 
option 
Value without 
option 
Option Value 
Yondelis 547,19 546,86 0,32 
Aplidine 502,70 502,33 0,36 
Kahalalide 236,48 236,11 0,37 
ES-285 210,76 210,29 0,47 
Preclinical 5 157,17 157,33 0,16 
 
 27
Table 4.6.a Valuation of PharmaMar with dependence between 
projects(euro millions, 2003) 
Drift 0.291 
Clayton param 
2,4 
Value with 
option 
Value without 
option 
Option Value 
Yondelis 545,96 545,64 0,31 
Aplidine 500,36 499,65 0,70 
Kahalalide 234,54 234,01 0,53 
ES-285 212,53 212,11 0,41 
Preclinical 5 156,33 156,03 0,29 
 
Table 4.7.a Valuation of PharmaMar with dependence between 
projects(euro millions, 2003) 
Drift 0.291 
Gaussian 
Value with 
option 
Value without 
option 
Option Value 
Yondelis -1,38 -2,66 1,27 
Aplidine -1,45 -2,89 1,44 
Kahalalide -0,40 -1,02 0,61 
ES-285 -0,89 -1,44 0,55 
Preclinical 5 -2,86 -5,44 2,5792 
 
 
Table 4.8.a Valuation of PharmaMar with dependence between 
projects(euro millions, 2003) 
Drift 0.291 
t 
Value with 
option 
Value without 
option 
Option Value 
Yondelis -1,38 -2,60 1,21 
Aplidine -1,65 -2,99 1,33 
Kahalalide -1,08 -2,11 1,03 
ES-285 -0,66 -1,89 1,23 
Preclinical 5 -3,00 -6,93 3,91 
 
Table 4.9.a Valuation of PharmaMar with dependence between 
projects(euro millions, 2003) 
Drift 0.291 
Fan Yu 
Value with 
option 
Value without 
option 
Option Value 
Yondelis 25,24 25,06 0,19 
Aplidine 14.96 14.77 0,18 
Kahalalide 4,54 4,49 0,05 
ES-285 2,65 2,57 0,07 
Preclinical 5 -6,92 -12,56 5,63 
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Table 4.10.b Valuation of PharmaMar with dependence between 
projects(euro millions, 2003) 
Drift 0.115 
Gumbel param 2 
Value with 
option 
Value without 
option 
Option Value 
Yondelis 42,70 37,92 4,77 
Aplidine 20,27 10,70 9,56 
Kahalalide 7,54 2,69 4,85 
ES-285 3,26 -4,17 7,43 
Preclinical 5 -8,18 -80,88 72,70 
 
Table 4.11.b Valuation of PharmaMar with dependence between 
projects(euro millions, 2003) 
Drift 0.115 
Gumbel param 
2,4 
Value with 
option 
Value without 
option 
Option Value 
Yondelis 42,33 34,65 7,68 
Aplidine 22,34 11,22 11,12 
Kahalalide 6,79 1,99 4,80 
ES-285 3,56 -5,68 9,25 
Preclinical 5 -8,99 -82,89 73,89 
 
Table 4.12.b Valuation of PharmaMar with dependence between 
projects(euro millions, 2003) 
Drift 0.115 
Frank param 2 
Value with 
option 
Value without 
option 
Option Value 
Yondelis 42,60 37,81 4,78 
Aplidine 21,67 11,88 9,78 
Kahalalide 7,82 3,00 4,82 
ES-285 2,99 -7,88 9,64 
Preclinical 5 -7,99 -80,17 72,17 
 
Table 4.13.b Valuation of PharmaMar with dependence between 
projects(euro millions, 2003) 
Drift 0.115 
Frank param 2,4 
Value with 
option 
Value without 
option 
Option Value 
Yondelis 42,97 37,99 4,97 
Aplidine 21,95 1,59 20,36 
Kahalalide 7,98 3,00 4,97 
ES-285 3,89 -5,74 9,64 
Preclinical 5 -7,88 -79,99 72,10 
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Table 4.14.b Valuation de PharmaMar with dependence between 
projects(euro millions, 2003) 
Drift 0.115 
Clayton param 2 
Value with 
option 
Value without 
option 
Option Value 
Yondelis 42,64 37,88 4,75 
Aplidine 21,09 12,00 9,09 
Kahalalide 8,00 3,65 4,35 
ES-285 3,29 -7,33 10,63 
Preclinical 5 -8,55 -79,80 71,25 
 
Table 4.15.b Valuation of PharmaMar with dependence between 
projects(euro millions, 2003) 
Drift 0.115 
Clayton param 
2,4 
Value with 
option 
Value without 
option 
Option Value 
Yondelis 42,76 37,99 4,77 
Aplidine 22,78 12,55 10,22 
Kahalalide 7,99 3,78 4,20 
ES-285 3,05 -7,72 10,78 
Preclinical 5 -7,34 -89,22 81,87 
 
Table 4.16.b Valuation of PharmaMar with dependence between 
projects(euro millions, 2003) 
Drift 0.115 
Gaussian 
Value with 
option 
Value without 
option 
Option Value 
Yondelis -0,66 -0,19 0,47 
Aplidine -0,38 -1,22 0,83 
Kahalalide -0,40 -1,02 0,61 
ES-285 -0,39 -0,93 0,53 
Preclinical 5 -1,03 -1,89 0,85 
 
Table 4.17.b Valuation of PharmaMar with dependence between 
projects(euro millions, 2003) 
Drift 0.115 
t 
Value with 
option 
Value without 
option 
Option Value 
Yondelis -14,88 -27,88 13,00 
Aplidine -16,78 -25,88 9,10 
Kahalalide -16,88 -19,29 2,40 
ES-285 -12,99 -23,11 10,11 
Preclinical 5 -19,88 -28,88 9,00 
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Table 4.18.b Valuation of PharmaMar with dependence between projects 
(euro millions, 2003) 
Drift 0.115 
Fan Yu 
Value with 
option 
Value without 
option 
Option Value 
Yondelis 32,83 29,06 3,77 
Aplidine 12,95 5,22 7,73 
Kahalalide 3,88 0,12 3,76 
ES-285 0,94 -5,18 6,12 
Preclinical 5 -8,00 -48,77 40,76 
 
 
 
 
 
 
 
Figure 1. Sensitivity Analysis: portfolio survival probabilities vs.  Time 
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Figure 2. Sensitivity Analysis for Yondelis: Drug value 
 And different drift values 
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Figure 3. Sensitivity Analysis for Yondelis: Abandon 
Option Values for different drift values 
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Figure 4. Sensitivity Analysis for Yondelis:  
Abandon paths percentage for different drift values 
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